Tuberculosis Therapeutics Market Size & Share Report, 2032

Tuberculosis Therapeutics Market - By Disease Type (Active TB, Latent TB), Therapy (First-Line Therapy, Second-Line Therapy), Route of Administration (Oral, Parenteral), Dosage Form (Tablets, Capsules), Distribution Channel & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp;Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp;Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp;Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp;Forecast model

1.5&nbsp;&nbsp;&nbsp;Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp;Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp;Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp;Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp;Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of tuberculosis

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing investment for healthcare infrastructure

3.2.1.3&nbsp;&nbsp;&nbsp;Rise in research and development activities

3.2.1.4&nbsp;&nbsp;&nbsp;Growing awareness and initiatives

3.2.2&nbsp;&nbsp;&nbsp;Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of treatment

3.3&nbsp;&nbsp;&nbsp;Growth potential analysis

3.4&nbsp;&nbsp;&nbsp;Regulatory landscape

3.5&nbsp;&nbsp;&nbsp;Reimbursement scenario

3.6&nbsp;&nbsp;&nbsp;Technological landscape

3.7&nbsp;&nbsp;&nbsp;Future market trends

3.8&nbsp;&nbsp;&nbsp;Pipeline analysis

3.9&nbsp;&nbsp;&nbsp;Gap analysis

3.10&nbsp;&nbsp;&nbsp;Porter&#39;s analysis

3.11&nbsp;&nbsp;&nbsp;PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp;Introduction

4.2&nbsp;&nbsp;&nbsp;Company matrix analysis

4.3&nbsp;&nbsp;&nbsp;Vendor matrix analysis

4.4&nbsp;&nbsp;&nbsp;Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp;Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp;Key trends

5.2&nbsp;&nbsp;&nbsp;Active TB

5.3&nbsp;&nbsp;&nbsp;Latent TB

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp;Key trends

6.2&nbsp;&nbsp;&nbsp;First-line therapy

6.3&nbsp;&nbsp;&nbsp;Second-line therapy

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp;Key trends

7.2&nbsp;&nbsp;&nbsp;Oral

7.3&nbsp;&nbsp;&nbsp;Parenteral

7.4&nbsp;&nbsp;&nbsp;Other route of administration

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Dosage Form, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp;Key trends

8.2&nbsp;&nbsp;&nbsp;Tablets

8.3&nbsp;&nbsp;&nbsp;Capsules

8.4&nbsp;&nbsp;&nbsp;Injection

8.5&nbsp;&nbsp;&nbsp;Other dosage forms

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp;Key trends

9.2&nbsp;&nbsp;&nbsp;Hospital pharmacies

9.3&nbsp;&nbsp;&nbsp;Retail pharmacies

9.4&nbsp;&nbsp;&nbsp;Online pharmacies

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp;U.S.

10.2.2&nbsp;&nbsp;&nbsp;Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp;Germany

10.3.2&nbsp;&nbsp;&nbsp;UK

10.3.3&nbsp;&nbsp;&nbsp;France

10.3.4&nbsp;&nbsp;&nbsp;Italy

10.3.5&nbsp;&nbsp;&nbsp;Spain

10.3.6&nbsp;&nbsp;&nbsp;Netherlands

10.3.7&nbsp;&nbsp;&nbsp;Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp;China

10.4.2&nbsp;&nbsp;&nbsp;Japan

10.4.3&nbsp;&nbsp;&nbsp;India

10.4.4&nbsp;&nbsp;&nbsp;Australia

10.4.5&nbsp;&nbsp;&nbsp;South Korea

10.4.6&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp;Brazil

10.5.2&nbsp;&nbsp;&nbsp;Mexico

10.5.3&nbsp;&nbsp;&nbsp;Argentina

10.5.4&nbsp;&nbsp;&nbsp;Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp;Saudi Arabia

10.6.2&nbsp;&nbsp;&nbsp;South Africa

10.6.3&nbsp;&nbsp;&nbsp;UAE

10.6.4&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles 

11.1&nbsp;&nbsp;&nbsp; Aventis Pharmaceuticals Limited

11.2&nbsp;&nbsp;&nbsp; Bayer Health Care

11.3&nbsp;&nbsp;&nbsp; Eli Lilly And Company

11.4&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services; Inc.

11.5&nbsp;&nbsp;&nbsp; Lupin

11.6&nbsp;&nbsp;&nbsp; Macleods Pharmaceuticals Ltd.

11.7&nbsp;&nbsp;&nbsp; Mylan N.V.

11.8&nbsp;&nbsp;&nbsp; Otsuka Pharmaceutical Co., Ltd.

11.9&nbsp;&nbsp;&nbsp; Pfizer Inc.

11.10&nbsp;&nbsp;&nbsp; Sanofi. 
&nbsp;

Tuberculosis Therapeutics Market

Get a free sample of this report